These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 33283772)

  • 1. Antibody-drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management.
    Sarangi SC; Sopory P; Pattnaik SS; Reeta KH
    Indian J Pharmacol; 2020; 52(5):402-413. PubMed ID: 33283772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical evidence on metronomic dosing in controlled clinical trials: a systematic literature review.
    Wichmann V; Eigeliene N; Saarenheimo J; Jekunen A
    Acta Oncol; 2020 Jul; 59(7):775-785. PubMed ID: 32275176
    [No Abstract]   [Full Text] [Related]  

  • 6. Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence.
    Kirti A; Simnani FZ; Jena S; Lenka SS; Kalalpitiya C; Naser SS; Singh D; Choudhury A; Sahu RN; Yadav A; Sinha A; Nandi A; Panda PK; Kaushik NK; Suar M; Verma SK
    Cancer Lett; 2024 Jul; 594():216990. PubMed ID: 38801886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving treatments for advanced gastric cancer: appraisal of the survival trend.
    Roberto M; Romiti A; Onesti CE; Zullo A; Falcone R; Marchetti P
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):717-29. PubMed ID: 27137418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for lung cancer in the era of personalized oncology.
    Ricciuti B; Lamberti G; Andrini E; Genova C; De Giglio A; Bianconi V; Sahebkar A; Chiari R; Pirro M
    Semin Cancer Biol; 2021 Feb; 69():268-278. PubMed ID: 31899248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current achievements and future perspectives of metronomic chemotherapy.
    Romiti A; Falcone R; Roberto M; Marchetti P
    Invest New Drugs; 2017 Jun; 35(3):359-374. PubMed ID: 27909934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy in metastatic colorectal cancer.
    Woo IS; Jung YH
    Cancer Lett; 2017 Aug; 400():319-324. PubMed ID: 28274890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic chemotherapy from rationale to clinical studies: a dream or reality?
    Gnoni A; Silvestris N; Licchetta A; Santini D; Scartozzi M; Ria R; Pisconti S; Petrelli F; Vacca A; Lorusso V
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):46-61. PubMed ID: 25656744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
    Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
    Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-drug conjugates: the new generation of biotechnological therapies against cancer.
    Melgarejo-Rubio G; Pérez-Tapia SM; Medina-Rivero E; Velasco-Velázquez MA
    Gac Med Mex; 2020; 156(3):228-235. PubMed ID: 32538994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
    Wu J; Waxman DJ
    Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer.
    Shi M; Ma T; Xi W; Jiang J; Wu J; Zhou C; Yang C; Zhu Z; Zhang J
    Trials; 2020 Mar; 21(1):249. PubMed ID: 32143730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of nanoparticulate delivery systems in metronomic chemotherapy.
    Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
    Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.